To elucidate this, the phase III trial KEYNOTE 789 is currently testing the efficacy and safety of pembrolizumab in addition to platinum–pemetrexed-based chemotherapy specifically in EGFR-mutated NSCLC in progression after an EGFR TKI, osimertinib included (NCT03515837). Here, EGFR is linked to non-small cell lung carcinoma.